Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Discovery Labs to Present At the Lazard Healthcare Conference
Nov 13, 2008 07:00 AM
- FDA Establishes Target Action Date of April 17, 2009 for Potential Approval of Discovery Labs' Surfaxin(r)
Nov 07, 2008 04:46 PM
- Discovery Labs Reports Third Quarter 2008 Financial Results
Nov 04, 2008 09:21 AM
- Discovery Labs Reports That It Has Not Yet Received FDA Notification Regarding Complete Response
Nov 04, 2008 09:15 AM
- Discovery Labs KL-4 Surfactant Data Presented At Two Key Medical Meetings
Oct 29, 2008 12:52 PM
- Discovery Labs Submits Complete Response to May 2008 FDA Approvable Letter for Surfaxin(r) for RDS
Oct 17, 2008 03:34 PM
- Discovery Labs Reports Technical Achievements Towards Gaining FDA Approval of Surfaxin
Sep 24, 2008 08:01 AM
- Discovery Labs' Aerosolized KL-4 Surfactant Selected for Evaluation in Phase 2a Cystic Fibrosis Clinical Trial
Sep 03, 2008 07:01 AM
- Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter
Aug 06, 2008 07:06 AM
- Discovery Labs Reports Second Quarter 2008 Financial Results
Aug 06, 2008 07:03 AM
- Form 4 ROSENTHALE MARVIN E For: Nov 18 (10K)
Nov 20, 2008 01:34 PM
- Form 4 DISCOVERY LABORATORIES For: Nov 13 Filed by: LOPEZ DAVID L (10K)
Nov 17, 2008 10:37 AM
- Form 4 DISCOVERY LABORATORIES For: Nov 17 Filed by: CAPETOLA ROBERT J (10K)
Nov 17, 2008 10:23 AM
- Form 4 CAPETOLA ROBERT J For: Nov 14 (10K)
Nov 14, 2008 04:05 PM
- Form 4 DISCOVERY LABORATORIES For: Oct 17 Filed by: LOPEZ DAVID L (10K)
Oct 17, 2008 01:37 PM
- Form 4 DISCOVERY LABORATORIES For: Oct 08 Filed by: ROSENTHALE MARVIN E (10K)
Oct 14, 2008 11:21 AM
- Form 4 ROSENTHALE MARVIN E For: Oct 03 (10K)
Oct 08, 2008 09:49 AM
- Form 4 Katzer Charles F For: Oct 01 (10K)
Oct 02, 2008 11:38 AM
- Form 4 CAPETOLA ROBERT J For: Sep 30 (10K)
Oct 01, 2008 12:05 PM
- Form 4 ROSENTHALE MARVIN E For: Sep 29 (10K)
Oct 01, 2008 11:27 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
DSCO
|
Compare to S&P
|
| YTD |
-53.95 %
|
-24.56 %
|
| 4 Weeks |
-45.90 %
|
-41.53 %
|
| 12 Weeks |
-52.63 %
|
-34.34 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: 0.00 %
|
|
Sales Growth in Last Quarter: -98.00 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
